Impact Biomedical SEC filings
Filter: All · 8-K · 10-Q · 10-K · Form 4
Completion of acquisition or disposition of assets · Delisting notice / failure to meet listing standard · Material modification of security holders' rights · Change in control · Departure/appointment of directors or officers · Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits
AI summary, unreviewedImpact BioMedical Inc. completes reverse merger into Cayman-incorporated PubCo, delists from NYSE American, and shareholders are left with a 4.80% stake
Submission of matters to a vote of security holders
AI summary, unreviewedImpact Biomedical Inc. stockholders approve Zoar merger agreement and director slate at November 13, 2026 special meeting
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedImpact Biomedical Announces SEC Effectiveness of Form F-4 for Zoar Business Combination; Stockholder Vote Set for November 13, 2026
Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits
AI summary, unreviewedImpact BioMedical Inc. Effects 1-for-12.62 Reverse Stock Split, Cutting Shares Outstanding From About 107.8 Million to About 8.6 Million
Regulation FD disclosure · Financial statements and exhibits
Regulation FD disclosure · Financial statements and exhibits